Compare AbCellera Biologics Inc (ABCL) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Booz Allen Hamilton Holding Corporation — how do they compare? AbCellera Biologics Inc trades at $8.94 (market cap $2.85B), while Booz Allen Hamilton Holding Corporation trades at $78.55 (market cap $9.37B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 3.3× AbCellera Biologics Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.03% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BAH | |
|---|---|---|
Market Cap | $2.85B | $9.37B |
Sector | Health | Industrials |
52-Week High | $9.76 | $111.63 |
52-Week Low | $2.78 | $59.71 |
Enterprise Value | $2.45B | $12.99B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Booz Allen Hamilton (BAH) trades at $76.05, up 2.87% with a bullish technical signal and strong earnings beats. Recent quarters show consistent EPS outperformance, with Q2 2026 actual EPS of $1.81 beating the $1.49 estimate. The stock benefits from a discounted valuation with a P/E of 11.94 and robust cash flow growth, though revenue declined 4.2% year-over-year in Q1 2027. National security demand remains a key driver, offset by civil segment weakness.
Outlook is cautiously positive with a consensus price target of $84.67, implying 11% upside. Strengths include high ROE of 68.11% and margin expansion, but risks involve elevated debt levels and revenue volatility. Investors should weigh valuation appeal against execution risks in government contracting.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
